Predictive role of topoisomerase IIα, gp170, Bcl-2, tumor burden, and histology in neoadjuvant chemotherapy for soft tissue sarcomas of the extremities

Autor:	G. Gino, E. Berardengo, Antonella Boglione, P. Pochettino, Alessandro Comandone, R. Piana, E. Brach Del Prever, C. Oliva, P. Bergnolo, P. Porrino, C. Faletti, A. Bernardi, A. Linari
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy Pathology Topoisomerase iiα Ifosfamide business.industry medicine.medical_treatment Tumor burden Locally advanced Soft tissue Histology Internal medicine medicine Immunohistochemistry business medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:10086-10086
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.10086
Popis:	10086 Background: Neoadjuvant chemotherapy (NACT) has a well established role in multidisciplinary treatment of soft tissue sarcomas (STS). Unfortunately no sure predictive factors have been identified in order to screen those patients who are going to benefit from NACT. Topoisomerase IIα (topo IIα) is a positive target for anthracyclines. Bcl-2 is a molecular target for alchilants. P-glycoprotein gp170 is a member of multidrug resistance (MDR) complex. This study aimed to evaluate if topo IIα, gp170, bcl-2, tumor burden and histology could predict the response to NACT in locally advanced STS of the extremities. Methods: Twenty-nine patients with STS of the extremities (median age 61 yrs, range 35-82) received a median of 3 cycles of Epirubicine and Ifosfamide as NACT. Topo IIα, gp170, bcl-2 were assessed by IHC either on pre-treatment biopsies and on post-treatment surgical specimens. Bioptical specimens were categorized in low and high expression according to a cut-off corresponding to the median value ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e5f3fdeb8c8b041eca6994547e1b2034 https://doi.org/10.1200/jco.2011.29.15_suppl.10086 Zobrazit plný text záznamu